03:08 PM EST, 11/25/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Tuesday its Imfinzi in combination with standard chemotherapy was approved in the US to treat adults with early-stage and locally advanced gastric and gastroesophageal junction cancers.

The approval follows Priority Review by the Food and Drug Administration and is based on event-free survival and overall survival data from a phase 3 trial, the company said.

A planned interim analysis showed that the drug regimen resulted in a 29% reduction in the risk of disease progression, recurrence or death compared with chemotherapy alone, the company said. About 78.2% of patients were event-free at one year, and the estimated two-year EFS rate was 67.4%, according to a statement.

Survival data analysis showed that the treatment lowered death risks by 22% compared with chemotherapy alone, the company said. Around 69% of patients treated with the drug regimen were alive at three years, the company said.

The safety profile was consistent with the known profiles of each medicine, according to the company.

Price: 93.04, Change: +1.52, Percent Change: +1.66